Soligenix IncNASDAQ:SNGXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.4310
- TODAY'S CHANGE (%)-0.0043 (-0.9878%)
- Bid / Lots0.4100/ 2
- Ask / Lots0.4200/ 1
- Open / Previous Close0.4100 / 0.4353
- Day Range
- 52 Week Range
- Volume1,027,079
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SNGX |
|---|---|---|
| 09:32 ET | 13780 | 0.417499 |
| 09:34 ET | 50632 | 0.4101 |
| 09:36 ET | 7298 | 0.4101 |
| 09:38 ET | 16359 | 0.41 |
| 09:41 ET | 1487 | 0.4101 |
| 09:43 ET | 5590 | 0.4101 |
| 09:45 ET | 2878 | 0.413498 |
| 09:50 ET | 8495 | 0.4105 |
| 09:52 ET | 401 | 0.41505 |
| 09:54 ET | 13494 | 0.4099 |
| 09:56 ET | 7510 | 0.40565 |
| 09:57 ET | 2811 | 0.4017 |
| 09:59 ET | 39631 | 0.4018 |
| 10:01 ET | 9750 | 0.4175 |
| 10:03 ET | 10579 | 0.4116 |
| 10:06 ET | 7050 | 0.41 |
| 10:08 ET | 22324 | 0.405791 |
| 10:10 ET | 2171 | 0.4059 |
| 10:12 ET | 12846 | 0.416 |
| 10:15 ET | 2137 | 0.396 |
| 10:17 ET | 6900 | 0.402 |
| 10:19 ET | 607 | 0.405 |
| 10:21 ET | 5673 | 0.415899 |
| 10:26 ET | 401 | 0.41 |
| 10:28 ET | 5032 | 0.4001 |
| 10:30 ET | 1014 | 0.4001 |
| 10:32 ET | 1588 | 0.416 |
| 10:33 ET | 8529 | 0.4002 |
| 10:35 ET | 3800 | 0.403089 |
| 10:37 ET | 200 | 0.4012 |
| 10:39 ET | 500 | 0.4012 |
| 10:42 ET | 1132 | 0.4012 |
| 10:44 ET | 2000 | 0.4013 |
| 10:46 ET | 11112 | 0.409 |
| 10:48 ET | 1500 | 0.4014 |
| 10:51 ET | 6745 | 0.4152 |
| 10:53 ET | 8709 | 0.4159 |
| 10:55 ET | 200 | 0.42 |
| 10:57 ET | 212 | 0.4101 |
| 11:00 ET | 2996 | 0.4101 |
| 11:02 ET | 677 | 0.4101 |
| 11:04 ET | 254 | 0.4101 |
| 11:06 ET | 10000 | 0.41 |
| 11:08 ET | 204 | 0.4102 |
| 11:09 ET | 41078 | 0.41015 |
| 11:11 ET | 42138 | 0.4002 |
| 11:13 ET | 26087 | 0.4001 |
| 11:15 ET | 52407 | 0.39655 |
| 11:18 ET | 29978 | 0.39655 |
| 11:20 ET | 53381 | 0.3974 |
| 11:22 ET | 32705 | 0.3965 |
| 11:24 ET | 1700 | 0.4129 |
| 11:26 ET | 473 | 0.397 |
| 11:27 ET | 5000 | 0.413 |
| 11:33 ET | 458 | 0.41 |
| 11:36 ET | 1000 | 0.40355 |
| 11:44 ET | 4700 | 0.4004 |
| 11:45 ET | 20991 | 0.413 |
| 11:47 ET | 195 | 0.41255 |
| 11:49 ET | 3000 | 0.4051 |
| 11:51 ET | 35003 | 0.41 |
| 11:56 ET | 6736 | 0.41 |
| 11:58 ET | 1248 | 0.41 |
| 12:00 ET | 9794 | 0.415 |
| 12:03 ET | 150 | 0.4125 |
| 12:07 ET | 172 | 0.42 |
| 12:14 ET | 11900 | 0.4089 |
| 12:16 ET | 546 | 0.4051 |
| 12:18 ET | 198 | 0.4051 |
| 12:20 ET | 100 | 0.405 |
| 12:21 ET | 234 | 0.41245 |
| 12:23 ET | 8807 | 0.419751 |
| 12:27 ET | 2842 | 0.41 |
| 12:36 ET | 1000 | 0.4197 |
| 12:38 ET | 8276 | 0.4196 |
| 12:39 ET | 6048 | 0.4051 |
| 12:41 ET | 1653 | 0.405001 |
| 12:45 ET | 800 | 0.406 |
| 12:48 ET | 500 | 0.419699 |
| 12:50 ET | 500 | 0.41285 |
| 12:54 ET | 600 | 0.4105 |
| 12:57 ET | 350 | 0.4197 |
| 01:03 ET | 500 | 0.409 |
| 01:06 ET | 500 | 0.409101 |
| 01:10 ET | 2403 | 0.4197 |
| 01:12 ET | 53454 | 0.419 |
| 01:14 ET | 3000 | 0.425 |
| 01:15 ET | 10000 | 0.408 |
| 01:19 ET | 141 | 0.409 |
| 01:24 ET | 1311 | 0.410001 |
| 01:28 ET | 100 | 0.4265 |
| 01:32 ET | 2564 | 0.42 |
| 01:35 ET | 15409 | 0.429 |
| 01:37 ET | 2200 | 0.421 |
| 01:44 ET | 1350 | 0.42 |
| 01:50 ET | 287 | 0.42 |
| 01:51 ET | 400 | 0.4242 |
| 01:55 ET | 1600 | 0.42 |
| 01:57 ET | 200 | 0.42 |
| 02:02 ET | 12173 | 0.4361 |
| 02:04 ET | 2000 | 0.441 |
| 02:13 ET | 1600 | 0.4201 |
| 02:15 ET | 100 | 0.42 |
| 02:27 ET | 200 | 0.426 |
| 02:33 ET | 10473 | 0.405 |
| 02:38 ET | 1400 | 0.4252 |
| 02:40 ET | 475 | 0.4252 |
| 02:42 ET | 1008 | 0.4252 |
| 02:44 ET | 4550 | 0.41 |
| 02:47 ET | 1100 | 0.4307 |
| 02:56 ET | 4034 | 0.438 |
| 02:58 ET | 1480 | 0.4306 |
| 03:03 ET | 805 | 0.4393 |
| 03:09 ET | 100 | 0.4306 |
| 03:14 ET | 3445 | 0.4306 |
| 03:16 ET | 632 | 0.4306 |
| 03:20 ET | 700 | 0.4306 |
| 03:25 ET | 1000 | 0.4306 |
| 03:27 ET | 860 | 0.4306 |
| 03:30 ET | 423 | 0.4311 |
| 03:34 ET | 250 | 0.44 |
| 03:43 ET | 900 | 0.4306 |
| 03:45 ET | 14000 | 0.4306 |
| 03:50 ET | 209 | 0.4306 |
| 03:54 ET | 7000 | 0.4306 |
| 03:56 ET | 1000 | 0.4306 |
| 03:57 ET | 1000 | 0.4311 |
| 03:59 ET | 3298 | 0.431 |
Apr 18, 2024
*DJ Soligenix Announces Pricing of $4.75M Public Offering, from 8:32AM ET on Thursday Apr 18, 2024 by Dow Jones
8:32AM ET on Thursday Apr 18, 2024 by Dow JonesSoligenix Announces Pricing of $4.75 Million Public Offering, from 8:30AM ET on Thursday Apr 18, 2024 by Dow Jones
8:30AM ET on Thursday Apr 18, 2024 by Dow Jones
Apr 15, 2024
DJ Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA, from 7:51AM ET on Monday Apr 15, 2024 by Dow Jones
7:51AM ET on Monday Apr 15, 2024 by Dow JonesFDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection, from 7:30AM ET on Monday Apr 15, 2024 by Dow Jones
7:30AM ET on Monday Apr 15, 2024 by Dow Jones
Apr 11, 2024
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection, from 7:30AM ET on Thursday Apr 11, 2024 by Dow Jones
7:30AM ET on Thursday Apr 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Soligenix Inc | 4.5M | -0.5x | --- |
Aditxt Inc | 3.9M | 0.0x | --- |
Biodexa Pharmaceuticals PLC | 3.2M | 0.0x | --- |
Azitra Inc | 5.6M | -0.1x | --- |
Theralink Technologies Inc | 5.5M | -0.3x | --- |
Lipella Pharmaceuticals Inc | 4.8M | -0.9x | --- |
Company Information
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19.
Contact Information
- Headquarters
- SUITE C-10, 29 EMMONS DRIVEPRINCETON, NJ, United States 08540
- Phone
- 609-538-8200
- Fax
- 609-452-6467
Executives
- Chairman of the Board, Chief Executive Officer and President
- Christopher Schaber
- Chief Financial Officer, Senior Vice President, Corporate Secretary
- Jonathan Guarino
- Senior Vice President, Chief Scientific Officer
- Oreola Donini
- Senior Vice President and Chief Medical Officer
- Richard Straube
- Independent Director
- Gregg Lapointe
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5M |
|---|---|
Revenue (TTM) | $839.4K |
Shares Outstanding | 10.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.91 |
EPS | $-0.92 |
Book Value | $0.24 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 5.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -964.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
